Astrana Health, Inc. (NASDAQ:ASTH - Free Report) - Investment analysts at William Blair boosted their Q2 2024 EPS estimates for Astrana Health in a report issued on Tuesday, May 7th. William Blair analyst R. Daniels now expects that the company will earn $0.40 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Astrana Health's current full-year earnings is $1.65 per share. William Blair also issued estimates for Astrana Health's FY2024 earnings at $1.39 EPS, Q3 2025 earnings at $0.41 EPS and Q4 2025 earnings at $0.33 EPS.
Other research analysts have also issued research reports about the stock. Truist Financial raised their price objective on shares of Astrana Health from $41.00 to $44.00 and gave the company a "hold" rating in a report on Friday, March 1st. Stifel Nicolaus reduced their price objective on shares of Astrana Health from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Jefferies Financial Group assumed coverage on Astrana Health in a research report on Monday, February 26th. They set a "buy" rating and a $50.00 target price for the company.
Get Our Latest Stock Analysis on Astrana Health
Astrana Health Stock Down 0.4 %
Shares of NASDAQ:ASTH traded down $0.16 during trading on Friday, hitting $38.89. 145,566 shares of the company were exchanged, compared to its average volume of 153,866. The firm has a market cap of $2.18 billion, a P/E ratio of 29.46, a P/E/G ratio of 1.20 and a beta of 1.12. Astrana Health has a 1-year low of $28.86 and a 1-year high of $45.71. The company has a quick ratio of 2.11, a current ratio of 2.11 and a debt-to-equity ratio of 0.42. The stock has a 50 day simple moving average of $40.12.
Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $404.36 million for the quarter, compared to analyst estimates of $413.84 million. Astrana Health had a return on equity of 11.52% and a net margin of 4.49%. The firm's revenue was up 19.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.42 EPS.
About Astrana Health
(
Get Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
